Zynerba Pharmaceuticals, Inc. Securities Litigation
On or around 01/27/2020 (Date of last review)
Filing Date: October 23, 2019
According to the Complaint, Zynerba Pharmaceuticals, Inc. was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba operates as a clinical stage specialty pharmaceutical company. The Company focuses on developing pharmaceutically-produced transdermal CBD therapies for rare and near-rare neuropsychiatric disorders.
The Complaint alleges that Defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Zygel was proving unsafe and not well-tolerated in the BELIEVE 1 Trial; (2) the foregoing created a foreseeable, heightened risk that Zynerba would fail to secure the necessary regulatory approvals for commercializing Zygel for the treatment of DEE in children and adolescents; and (3) as a result, Zynerba’s public statements were materially false and misleading at all relevant times.
On January 9, 2020, the Court issued an Order appointing Lead Plaintiffs and Counsel.
Company & Securities Information
Defendant: Zynerba Pharmaceuticals, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: ZYNE
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Andy Velayos, et al. v. Zynerba Pharmaceuticals, Inc., et al.